The market keeps trying to put SMX (NASDAQ:SMX) in a box. Plastics. Metals. Electronics. Rubber. Fashion. Every time a new ...
Scientists from Turkey have designed a next-generation implantable biosensor using genetically engineered E. coli for ...
Countless bacterial species share cramped environments where competition for space and resources is fierce. Some rely on a ...
The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...
News-Medical.Net on MSN
New molecular ruler enables precise measurement of toxic Tau fibrils in fluid samples
Researchers have developed a new tool, FibrilPaint combined with the FibrilRuler test, that allows scientists to directly ...
The fashion industry has spent years promising circularity. Recycling initiatives, take-back bins, and ESG roadmaps have ...
TipRanks on MSN
4D Molecular Therapeutics expands phase 3 trial enrollment
D Molecular Therapeutics ( ($FDMT) ) has shared an update. On December 10, 2025, 4D Molecular Therapeutics announced amendments to its Phase 3 ...
Targeting receptors for erythropoietin on dendritic cells may be a viable strategy for treating MS and other diseases, ...
Allergic sensitization follows distinct regional patterns, and molecular IgE profiling can reveal these profiles in detail. An international research team has now demonstrated both phenomena in a ...
PLC (NASDAQ:SMX), the global leader in molecular-based material authentication and digital product passports, today announced ...
"With ALMA, we can now see the atmosphere of a dying star with a level of clarity in a similar way to what we do for the sun.
University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results